SG Americas Securities
CTIC

SG Americas Securities’s CTI BioPharma Corp. (DE) Common Stock CTIC Stock Holding History

SG Americas Securities’s Portfolio CTIC Stock Details CTIC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-49,149
Closed -$295K – 3678
2022
Q4 		$295K Sell
49,149
-2,555
-5% -$13.9K ﹤0.01% 1936
2022
Q3 		$301K Sell
51,704
-52,019
-50% -$324K ﹤0.01% 1994
2022
Q2 		$619K Buy
+103,723
New +$531K 0.01% 1765
2019
Q3 		– Sell
-56,132
Closed -$48K – 3408
2019
Q2 		$48K Buy
56,132
+17,163
+44% +$15.8K ﹤0.01% 2920
2019
Q1 		$38K Sell
38,969
-8,237
-17% -$8.67K ﹤0.01% 3233
2018
Q4 		$35K Buy
+47,206
New +$77.6K ﹤0.01% 2871
2016
Q2 		– Sell
-15,796
Closed -$84K – 3303
2016
Q1 		$84K Buy
+15,796
New +$126K ﹤0.01% 2668
2014
Q1 		– Sell
-2,509
Closed -$48K – 3034
2013
Q4 		$48K Sell
2,509
-897
-26% -$16.3K ﹤0.01% 2470
2013
Q3 		$56K Buy
+3,406
New +$39.5K ﹤0.01% 2782

Other funds holding CTIC

State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
BL
Bleichroeder LP New York $559M AUM 83.7% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

SG Americas Securities's CTIC Position: Q1 2023 in Review

SG Americas Securities sold out of CTI BioPharma Corp. (DE) Common Stock (CTIC) in Q1 2023, closing a stake of 49,149 shares — an estimated $295K sold.

SG Americas Securities first reported a position in CTIC in Q3 2013 and held it in 9 quarters. The position peaked at $619K in Q2 2022. 133 funds tracked by Wall St. Rank hold CTIC as of Q1 2023.

  • SG Americas Securities reported no remaining CTI BioPharma Corp. (DE) Common Stock position as of Q1 2023 after selling out during the quarter.
  • SG Americas Securities sold 49,149 CTI BioPharma Corp. (DE) Common Stock shares in Q1 2023, an estimated $295K.
  • SG Americas Securities first reported a position in CTI BioPharma Corp. (DE) Common Stock in Q3 2013 and held it in 9 quarters.
  • SG Americas Securities's CTI BioPharma Corp. (DE) Common Stock position peaked at $619K in Q2 2022.
  • 133 funds tracked by Wall St. Rank held CTI BioPharma Corp. (DE) Common Stock as of Q1 2023.

Based on SG Americas Securities's 13F filing for Q1 2023, filed 28 Apr 2023.